Vincenzo De Filippis

Prof. Dr. Vincenzo De Filippis

Department of Pharmaceutical and Pharmacological Sciences, University of Padua School of Medicine, via Marzolo, 5, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1991 in Biochemistry
Verified
Journal Article
Closed access
STSalvatore Toma
Salvatore Toma
SCSusanna Campagnoli
Susanna Campagnoli
IMImmacolata Margarit
Immacolata Margarit
RGRoberto Gianna
Roberto Gianna
GGGuido Grandi
Guido Grandi
AFAngelo Fontana
Angelo Fontana

1 May 2006 in Protein Science
Verified
Journal Article
Closed access
PDF file
Vincenzo De FilippisVincenzo De Filippis
Vincenzo De Filippis
RFRoberta Frasson
Roberta Frasson
AFAngelo Fontana
Angelo Fontana

1 September 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
Alexey SokolovAlexey Sokolov
Alexey Sokolov
LALaura Acquasaliente
Laura Acquasaliente
VKValeria Kostevich
Valeria Kostevich
RFRoberta Frasson
Roberta Frasson
EZElena T. Zakharova
Elena T. Zakharova
Vincenzo De FilippisVincenzo De Filippis
Vincenzo De Filippis

1 June 2004 in Protein Science
Verified
Journal Article
Open access
PDF file
Vincenzo De FilippisVincenzo De Filippis
Vincenzo De Filippis
SBSilvia De Boni
Silvia De Boni
EDElisa De Dea
Elisa De Dea
DDDaniele Dalzoppo
Daniele Dalzoppo
CGClaudio Grandi
Claudio Grandi
AFAngelo Fontana
Angelo Fontana
7‐Azatryptophan (AW), a noncoded isostere of tryptophan (W), possesses interesting spectral properties. In particular, the presence of a nitrogen atom at position 7 in the indolyl nucleus of AW results in a red shift of the absorption maximum and fluorescence emission by 10 and 46 nm, respectively, compared to W. In the present work, we report the chemical synthesis and the conformational and functional characterization of an analog (denoted as Y3AW) of the N‐terminal domain 1–47 of hirudin, a highly potent thrombin inhibitor, in which Tyr 3 has been replaced by AW. The results obtained were compared with those of the cooresponding Y3W analog. We found that the replacement W → AW reduces affinity for thrombin by 10‐fold, likely because of the lower hydrophobicity of AW compared with that of W. Measurements of the resonance energy transfer effect, which was observed between Tyr13 and the amino acid at position 3 upon disulfide‐coupled folding, demonstrate that AW behaves as a better energy acceptor than W for studying protein renaturation. The interaction of Y3AW with thrombin was studied by exciting the sample at 320 nm and recording the change in fluorescence of Y3AW on binding to the enzyme. Our results indicate that the fluorescence of AW of hirudin 1–47 in the Y3AW–thrombin complex is strongly quenched, possibly because of the presence of two structural water molecules at the hirudin–thrombin interface that can promote the nonradiative decay of AW in the excited state. The data herein reported demonstrate that the incorporation of AW can be of broad applicability in the study of protein folding and protein–protein interaction.

11 April 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
NPNicola Pozzi
Nicola Pozzi
LALaura Acquasaliente
Laura Acquasaliente
RFR. Frasson
R. Frasson
ACA. Cristiani
A. Cristiani
Stefano MoroStefano Moro
Stefano Moro
Vincenzo De FilippisVincenzo De Filippis
Vincenzo De Filippis
Background This work was aimed at characterizing the interaction of β2‐glycoprotein I (β2GPI), an abundant plasma protein of unknown function, with human thrombin, the final effector protease in the coagulation cascade. Methods The β2GPI–thrombin interaction was studied by surface plasmon resonance (SPR), fluorescence, and molecular modeling. The effect of β2GPI on the procoagulant (fibrin generation and platelet aggregation) and anticoagulant (protein C activation) functions of thrombin were investigated with turbidimetric, immunocytofluorimetric and enzymatic assays. Results SPR and fluorescence data indicated that β2GPI tightly bound thrombin (Kd = 34 nm) by interacting with both protease exosites, while leaving the active site accessible. This picture is fully consistent with the theoretical model of the β2GPI–thrombin complex. In particular, blockage of thrombin exosites with binders specific for exosite‐1 (hirugen and HD1 aptamer) or exosite‐2 (fibrinogen γ′‐peptide and HD22 aptamer) impaired the β2GPI–thrombin interaction. Identical results were obtained with thrombin mutants having one of the two exosites selectively compromised by mutation (Arg73Ala and Arg101Ala). Fluorescence measurements indicated that β2GPI did not affect the affinity of the enzyme for active site inhibitors, such as p‐aminobenzamidine and the hirudin(1–47) domain, in agreement with the structural model. β2GPI dose‐dependently prolonged the thrombin clotting time and ecarin clotting time in β2GPI‐deficient plasma. β2GPI inhibited thrombin‐induced platelet aggregation (IC50 = 0.36 μm) by impairing thrombin cleavage of protease‐activated receptor 1 (PAR1) (IC50 = 0.32 μm), both on gel‐filtered platelets and in whole blood. Strikingly, β2GPI did not affect thrombin‐mediated generation of the anticoagulant protein C. Conclusions β2GPI functions as a physiologic anticoagulant by inhibiting the key procoagulant activities of thrombin without affecting its unique anticoagulant function.

1 April 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
GSGiorgia Scapin
Giorgia Scapin
PSPatrizio Salice
Patrizio Salice
STSimone Tescari
Simone Tescari
Enzo MennaEnzo Menna
Enzo Menna
Vincenzo De FilippisVincenzo De Filippis
Vincenzo De Filippis
FFFrancesco Filippini
Francesco Filippini